Healthcare Purchasing News
  • Magazine
  • Continuing Education
  • Webinars
  • Whitepapers
  • Videos
  • Events
  • Hall of Fame
  • Advertise
  • Source Guide
  • Subscribe
  • Sourcing & Logistics
  • Sterile Processing
  • Surgical & Critical Care
  • Patient Satisfaction
  • Infection Prevention
  • EVS & Facility Services
  • Healthcare IT
  • Regulatory
  • Topics
    Sourcing & LogisticsSterile ProcessingSurgical & Critical CarePatient SatisfactionInfection PreventionEVS & Facility ServicesHealthcare ITRegulatory
    Resources
    HPN Source GuideContinuing EducationWebinarsWhitepapersVideosEventsHall of FameAdvertiseAd Specs
    User Tools
    SubscribeContact UsAbout UseNewsletterMagazinesPrivacy PolicyTerms & Conditions
    https://www.facebook.com/hpnonline
    https://www.linkedin.com/company/healthcare-purchasing-news/
    https://twitter.com/HPN_Online
    1. Infection Prevention

    Pfizer and BioNTech submit application for latest COVID-19 booster for children under 5

    Dec. 5, 2022
    Photo 203819205 © Julián Rovagnati | Dreamstime.com
    Dreamstime Xs 203819205 (1)

    Pfizer Inc. and BioNTech SE have announced that the companies have submitted an application to the U.S. Food and Drug Administration (FDA) for emergency use authorization (EUA) of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine as the third 3-µg dose in the three-dose primary series for children 6 months through 4 years of age. With the high level of respiratory illnesses currently circulating among children under 5 years of age, updated COVID-19 vaccines may help prevent severe illness and hospitalization.

    If authorized, children in this age group would receive a primary series consisting of two 3-µg doses of the original Pfizer-BioNTech COVID-19 Vaccine followed by a third 3-µg dose of the Omicron BA.4/BA.5-adapted bivalent vaccine. An application to extend Pfizer and BioNTech’s Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine marketing authorization in the EU to include children ages 6 months through 4 years is under discussion with the European Medicines Agency (EMA).

    The Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine is currently authorized as a booster dose for ages 5 years and older in the U.S. and European Union (EU).

    The Pfizer-BioNTech COVID-19 Vaccines (COMIRNATY) are based on BioNTech’s proprietary mRNA technology and were developed by both BioNTech and Pfizer. BioNTech is the Marketing Authorization Holder for BNT162b2 (Original) and BNT162b2 Bivalent (Original/Omicron BA.4/BA.5) in the United States, the European Union, the United Kingdom, Canada and other countries, and the holder of emergency use authorizations or equivalents in the United States (jointly with Pfizer) and other countries.

    Pfizer release

    Latest in Infection Prevention

    1200085423 © deepblue4you | gettyimages.com
    Infection Prevention

    Sanford Health’s Instrument Quality Conundrum

    Janette Wider
    Nov. 28, 2023
    Photo 197864141 © Dizain777 | Dreamstime.com
    Infection Prevention

    WHO sees Uptick of Respiratory Illnesses in Children in Northern China

    Nov. 27, 2023
    Photo 117616099 | Antimicrobial Resistance © Designer491 | Dreamstime.com
    Infection Prevention

    IDSA announces Antimicrobial Stewardship Centers of Excellence designation recipients

    Janette Wider
    Nov. 21, 2023
    Photo 32161147 © Fasphotographic | Dreamstime.com
    Infection Prevention

    Global measles threat continues to grow as another year passes with millions of children unvaccinated

    Nov. 21, 2023
    Photo 281959520 © Zelwanka | Dreamstime.com
    Infection Prevention

    Expedited availability of additional doses of new RSV immunization for infants

    Nov. 20, 2023
    Healthcare Purchasing News
    https://www.facebook.com/hpnonline
    https://www.linkedin.com/company/healthcare-purchasing-news/
    https://twitter.com/HPN_Online
    • About Us
    • Contact Us
    • Advertise
    • Do Not Sell or Share
    • Privacy Policy
    • Terms & Conditions
    © 2023 Endeavor Business Media, LLC. All rights reserved.
    Endeavor Business Media Logo